BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Durham, North Carolina. The company focuses on orphan & autoimmune diseases, and antivirals. The company's most advanced drug candidate is the antiviral Peramivir, which is approved in Japan, Korea and China. It was authorized by the FDA for emergency use in the treatment of patients hospitalized with influenza during the 2009-10 influenza A virus subtype H1N1 pandemic. Wikipedia.
BioCryst Pharmaceuticals | Date: 2014-06-24
The invention provides unit dosage forms, kits, and methods and useful for treating viral infections.
BioCryst Pharmaceuticals | Date: 2014-02-26
The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.
BioCryst Pharmaceuticals | Date: 2011-10-14
The present invention is directed to methods and compositions for inhibition of viral nucleic acid polymerases, such as RNA and DNA polymerases, and methods and compositions that are useful for treating viral infections in subjects. The methods comprise administering to the subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, or a composition comprising a compound of formula I, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier. The composition or method may optionally comprise one or more additional anti-viral agents.
BioCryst Pharmaceuticals | Date: 2011-05-09
BioCryst Pharmaceuticals | Date: 2014-05-14
Disclosed are novel compounds comprising an imino-ribose derivative covalently linked to a carbocycle or heterocycle. Pharmaceutical compositions comprising the compounds of the invention are also described. Methods of inhibition, treatment and/or suppression of viral infections with the compounds of the invention are also described. The compositions or methods may optionally comprise one or more additional anti-viral agents.